Jump to content

Zoledronic acid = cheaper Pamidronate

Recommended Posts

Risk of skeletal-related events in patients with advanced prostate cancer treated with pamidronate or zoledronic Acid - Abstract

Thursday, 19 August 2010

Pharmacy Outcomes Research Group, Kaiser Permanente, Downey, CA.

Pamidronate and zoledronic acid are used for the prevention of skeletal-related events (SREs) in patients with advanced solid tumors, particularly breast and prostate cancers. There have been no head-to-head clinical trials comparing pamidronate and zoledronic acid among patients with advanced prostate cancer.

To estimate the risk of developing an SRE among men with metastatic prostate cancer after being treated with either pamidronate or zoledronic acid.

A retrospective cohort study was conducted, using data from Kaiser Permanente's Southern California Region. The cohort included men aged >/=18 years diagnosed with prostate cancer from 1998 to 2004 who received at least 1 infusion of either pamidronate or zoledronic acid after their cancer diagnosis. Patients receiving both drugs and those with a documented SRE prior to diagnosis were excluded. The primary outcome of SREs was defined using diagnosis codes for fractures, spinal cord compression, radiation to bone, and hypercalcemia of malignancy. Secondary outcomes were deterioration in renal function, based on serum creatinine laboratory results, and mortality. Multivariate logistic regression was used to predict SREs and mortality risk for pamidronate compared to zoledronic acid. The proportion of patients with renal function deterioration was analyzed using chi(2) tests.

The cohort included 118 patients treated with pamidronate and 274 treated with zoledronic acid. Results showed no significant difference in risk of SREs for pamidronate versus zoledronic acid (OR 0.99; 95% CI 0.59 to 1.67; p = 0.98). No significant difference was found in renal function deterioration (chi(2) 2.08; p = 0.15) or mortality (OR 0.71; 95% CI 0.43 to 1.17; p = 0.18).

For patients with prostate cancer, the choice between these 2 bisphosphonates must be balanced between the shorter infusion time of zoledronic acid versus its increased costs. We found no evidence for a difference in outcomes; therefore, pamidronate is an effective choice where clinic capacity permits.

Written by:

Spence MM, Hui RL, Chan J, Schottinger JE.

Reference: Ann Pharmacother. 2010 Aug 3. Epub ahead of print.

PubMed Abstract

PMID: 20682850 Forum: Other prostate cancer topics including radiation Title: Zoledronic acid = cheaper Pamidronate

This extract can be found on http://PubMed.com, and is in the public domain.

On PubMed.com there will be a link to the full paper (often $30, sometimes free).

Any highlighting (except the title) is not by the author, but by Jim Marshall.

Jim is not a doctor.

This page was found on the Advanced Prostate Cancer Community for Australian men at http://advancedprost...lia.ipbhost.com.

The link is hard to remember.

An easier way to find it is to go to JimJimJimJim.com and click on Prostate.

That's the word Jim four times, no spaces, followed by .com.

If you need other help - to perhaps find someone to talk to or a local support group:

Click on the Contact Jim button at http://JimJimJimJim.com.

Link to comment
Share on other sites


This topic is now archived and is closed to further replies.

  • Create New...